Document Classification

Section Type: RESULTS

Text: At a median follow-up time of 30. 1 months, we observed similar overall incidence of cardiac AEs (letrozole, 4. 8 % ; tamoxifen, 4. 7 %), more grade 3 to 5 cardiac AEs on letrozole (letrozole, 2. 4 % ; tamoxifen, 1. 4 % ; P =. 001) -- an excess only partially attributable to prior hypercholesterolemia -- and more overall (tamoxifen, 3. 9 % ; letrozole, 1. 7 % ; P <. 001) and grade 3 to 5 thromboembolic AEs on tamoxifen (tamoxifen, 2. 3 % ; letrozole, 0. 9 % ; P <. 001).